Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
2 participants
INTERVENTIONAL
2020-02-26
2020-02-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Unlike allergic asthma, this form does not today demonstrated its genetic character. However, the existence of familial forms of asthma in this region Pays de La Loire led us to hypothesize the existence of genetic variations can explain some familial forms of non-atopic asthma. Corresponding genes may be relevant to understanding the pathophysiological pathways involved in the more common sporadic forms.
The investigators propose a study combining genetic linkage analysis and complete sequencing exomes to identify one or more genetic abnormalities associated with non-atopic asthma. The clinical stage essential for mutation identification is to identify and recruit large families with members affected by non-atopic asthma and ensure accurate phenotyping of all individuals recruited over several generations.
The aim of this study is to create a cohort of families who have more members within them non-atopic asthma. A high genetic combined exome sequencing throughput analysis in a family linkage study will then reveal the presence or absence of genetic variations associated with intrinsic asthma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Risk Factors for Severe Asthma
NCT00090740
Effect of Heredity and Environment on Asthma Development and Severity in Puerto Rican Children
NCT00461227
Association Between Genetic Polymorphisms and Type 2 Asthma in Children
NCT06840717
Novel Gentic Variations Contributing to Asthma Susceptability in Saudi Arabia
NCT01216215
TNF Alpha in Refractory Asthma
NCT00276029
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
These patients will be treated as index case.
The investigator will conduct a family tree of the index case to identify families where the number of healthy individuals and those with non-atopic asthma makes relevant a family genetic study. Before initiating the family screening, it is necessary to have notion of at least two individuals carrying non-atopic asthma at least two generations in the family.
Related agreeing to participate in this study will be included.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
blood sample for genetic evaluation
a blood sample is collected once for genetic analysis
demonstration of genetic mutations causing non-atopic asthma
recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
demonstration of genetic mutations causing non-atopic asthma
recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Major
* Lack of respiratory disease documented in the medical record other than asthma
* Severe Asthma by definition ATS / ERS 2014:
* Treatment with high doses of CI and beta2 agonists for long-acting (B2LDA) or anti leukotriene or theophylline during the previous year or oral corticosteroids (CO) more than 50% from the previous year to prevent loss of control asthma.
* Asthma "uncontrolled" (at least 1 criteria):
* ACT \<20 and / or ACQ\> 1.5 (Asthma Control Test)
* 2 courses or more CO in the previous year
* 1 hospitalization for asthma in the previous year
* FEV \<80% predicted despite bronchodilators.
* Examination or medical record to find at least one member of the genetically non-atopic asthma associated family
* Prick negative tests for common allergens, questionnaire seeking negative atopy (SFAR Love) Phadiatop or negative diagnosis of non-atopic asthma confirmed by the adjudication committee
* informed and written consent of the patient to participate in the study
* Affiliated to a social security scheme
Exclusion Criteria
* Minors
\- Known associated respiratory pathologies (COPD, bronchial dilatation, diffuse infiltrating pneumopathy)
* Major Trust
* Subject having demonstrated the inability or refusal to sign an informed consent
Relatives' patients:
* Major
* Related to the 1st and 2nd level of the index case or another member with family
* Related with or without a asthma (atopic or non-atopic)
* Informed and written consent of the patient to participate in the study Affiliated to a social security scheme
* Pregnant women
* Minors
* Major Trust
* Subject having demonstrated the inability or refusal to sign an informed consent
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nantes - Service de Pneumologie - HGRL
Nantes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-A00922-49
Identifier Type: OTHER
Identifier Source: secondary_id
RC15_0354
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.